Breadcrumb Navigation:
Home > What We Fund > Available Funding
Available Funding
Several funding options are available through Fast Forward, facilitated by Request For Proposal (RFP) cycles. Specific and rolling RFP's are accepted for review on the following schedule.
General Fund
Click here to read program details from former year
Funding available for therapeutic development programs treating symptoms of multiple sclerosis.
Support is available for early stage companies working on therapeutic strategies to ameliorate the symptoms of MS. Examples of projects can include, but are not limited to the following areas:
-
Fatigue
-
Pain
-
Cognitive Impairment
Note: We will be announcing program priorities, Requests for Applications and other funding mechanisms in 2012.
Collaborative Fund
RFP's will be accepted until May 1, 2012 through the Fast Forward and EMD Serono Collaborative Fund. Click here for RFP details.
This RFP is focused on the following project areas:
- Development of therapeutics that target specific B cell lineages involved in MS pathology
- Identification of surrogate or endogenous ligands for Orphan G Protein-Coupled Receptors (GPCRs) expressed exclusively or primarily in the central nervous system (CNS) that relate to the pathology of MS
Applicants with related programs in other disease areas (e.g. GPCRs associated with other neurodegenerative diseases, neuronal repair, or oligodendrocyte differentiation) that meet the RFP scope and the other program requirements (translational stage, issued patents or path to patentability) are encouraged to apply.